The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Le H. Hua,Carrie Hersh,Peter Morten,Jeanette Kusel,Feng Lin,Julie Cave,Stefan Varga,Vivian Herrera,John Ko

The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

2019

Le H. Hua
Carrie Hersh
Peter Morten
Jeanette Kusel
Feng Lin
Julie Cave
Stefan Varga
Vivian Herrera
John Ko

BACKGROUND: Cost-effectiveness analyses tend not to take into account the availability of lower-priced generics following loss of exclusivity (LOE) of branded products. By not considering these gen...

Keywords:

Interferon beta-1a
Oncology
Physical therapy
Fingolimod
Multiple sclerosis
Cost-effectiveness analysis
Medicine
Internal medicine
relapsing remitting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations